Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Lithium, an effective treatment for mania and the prevention of recurrent episodes of both mania and depression in patients with manic depressive illness, exerts multiple biochemical effects. However, any clinically relevant site of action of lithium must occur at therapeutic concentrations attained in the brain of patients and must account for the lag period accompanying onset of action as well as effects persisting beyond discontinuation of treatment. This monovalent cation acts as a potent uncompetitive inhibitor in the receptor-coupled breakdown of inositol phospholipids, resulting in a relative depletion of inositol and an alteration in the generation of diacylglycerol, an endogenous activator of protein kinase C. In our laboratory, we are examining the action of chronically administered lithium on posttranslational modification of specific phosphoproteins involved in regulating signal transduction in the brain. We have found that chronic, but not acute, administration of lithium in rats markedly reduces a major phosphoprotein substrate of protein kinase C in the hippocampus, an effect that persists beyond the cessation of lithium treatment. This protein, myristoylated alanine-rich C kinase substrate ("MARCKS"), is implicated in synaptic neurotransmission, calcium regulation, and cytoskeletal restructuring. These findings have relevance for the long-term action of lithium in stabilizing an underlying dysregulation in the brain and may move us closer to formulating a molecular basis of manic depressive illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
Cited by
Molecular Targets of Lithium Action
Phiel, C. J., & Klein, P. S. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 515
Meyer, B., Johnson, S. L., & Winters, R. (2001) · Journal of Psychopathology and Behavioral Assessment · doi:10.1023/a:1010929402770 · Cited by 326
“Evidence is converging for genetic links (Craddock & Jones, 1999; Pekkarinen, Terwilliger, Bredbacka, Lonnqvist, & Peltonen, 1995) as well as neurochemical and neuroanatomic abnormalities (Goodnick, 1997; Goodwin & Jamison, 1990; Lenox & Watson, 1994; Norris, Krishnan, & Ahearn, 1997).”
Manji, H. K., & Lenox, R. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00235-8 · Cited by 241
Self-citationLithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140
“Cytoskeletal growth stabilisation and plasticity appear to lead to stabilisation of aberrant neuronal activity, a conceptually attractive target for a mood-stabilising drug [Lenox and Watson, 1994].”
Background
Metadata
- Authors
- Lenox, R. H., & Watson, D. G.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-02-01
- Volume
- 40
- Issue
- 2
- Pages
- 309-314
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1950036781
- Cited by
- 81
- References
- 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness. https://app.cochat.ai/papers/10.1093/clinchem/40.2.309
- The paper
- Lenox, R. H., & Watson, D. G. (1994). Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness. Clinical Chemistry. https://doi.org/10.1093/clinchem/40.2.309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.